Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics
Biomaterials Research · 2024-01 · 28
DOI: 10.34133/bmr.0017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 22.05.2024. Verfasst von Yeji Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Science and ICT, South Korea, Ministry of Food and Drug Safety, Ministry of Education.
Abstract (Originalsprache)
During the COVID-19 pandemic, mRNA vaccines emerged as a rapid and effective solution for global immunization. The success of COVID-19 mRNA vaccines has increased interest in the use of lipid nanoparticles (LNPs) for the in vivo delivery of mRNA therapeutics. Although mRNA exhibits robust expression profiles, transient protein expression is often observed, raising uncertainty regarding the frequency of its administration. Additionally, various RNA therapeutics may necessitate repeated dosing to achieve optimal therapeutic outcomes. Nevertheless, the impact of repeated administrations of mRNA/LNP on immune responses and protein expression efficacy remains unclear. In this study, we investigated the influence of the formulation parameters, specifically ionizable lipids and polyethylene glycol (PEG) lipids, on the repeat administration of mRNA/LNP. Our findings revealed that ionizable lipids had no discernible impact on the dose-responsive efficacy of repeat administrations, whereas the lipid structure and molar ratio of PEG lipids were primary factors that affected mRNA/LNP performance. The optimization of the LNP formulation with PEG lipid confirmed the sustained dose-responsive efficacy of mRNA after repeated administrations. This study highlights the critical importance of optimizing LNP formulations for mRNA therapeutics requiring repeated administrations.
Autor:innen und Institutionen
- College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
ORCID-Profile: Yeji Lee, Michaela Jeong, Gyeongseok Lee, Jeongeun Park, Hyein Jung, Hyukjin Lee
Förderung
- Ministry of Science and ICT, South Korea
- Ministry of Food and Drug Safety
- Ministry of Education
Zitieren
APA
Lee, Y., Jeong, M., Lee, G., Park, J., Jung, H., Im, S., & Lee, H. (2024). Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics. Biomaterials Research, 28. https://doi.org/10.34133/bmr.0017
Vancouver
Lee Y, Jeong M, Lee G, Park J, Jung H, Im S, et al. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics. Biomaterials Research. 2024;28. doi:10.34133/bmr.0017
BibTeX
@article{Lee2024,
author = {Lee, Yeji and Jeong, Michaela and Lee, Gyeongseok and Park, Jeongeun and Jung, Hyein and Im, Seongeun and Lee, Hyukjin},
title = {Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics},
journal = {Biomaterials Research},
year = {2024},
volume = {28},
doi = {10.34133/bmr.0017}
}
EUVIMED